Although the cognitive and functional benefits of these drugs remain uncertain and show small effect sizes, they effectively demonstrated target engagement and disease-modifying potential by reducing Aβ load and improved multiple biomarker measures linked to AD pathology, including amyloid burden on PET and CSF Aβ40, Aβ42, and p-tau [16,24,71]. The gene discussed is MAPT; the disease is amyloidosis.